GE Healthcare has completed the installation of its FlexFactory biomanufacturing platform at JHL Biotech’s Research Center and manufacturing plant in Hsinchu, Taiwan. The new manufacturing platform will follow cGMP and be fully operational by the end of this year.
 
GE’s FlexFactory is a centrally automated biomanufacturing platform that, according to the company, allows manufacturers to quickly and easily establish manufacturing capacity within an existing building or as part of a new facility. FlexFactory is comprised of single-use technologies and associated process hardware, as well as all necessary automation and control components for manufacturing of biopharmaceuticals.
 
JHL Biotech’s FlexFactory in Taiwan will be used for cell line development, process development, and cGMP manufacturing for preclinical and early-stage clinical trials. It will also support technology transfer.
 
Olivier Loeillot, general manager of Enterprise Solutions, GE Healthcare Life Sciences, said, “Our offering of tools, technologies and services for biomanufacturing has strength in both breadth and depth. For JHL Biotech we have been able to take an approach, which recognizes the differing requirements of multiple sites, whilst at the same time allowing them to replicate processes.”
 
Racho Jordanov, co-founder, president and chief executive officer of JHL Biotech, said, “JHL Biotech will make world-class biopharmaceuticals affordable to more people by utilizing innovations such as FlexFactory. Our biomanufacturing capability increases with the installation of cGMP manufacturing in our Taiwan facility. Because our biomanufacturing capabilities are shared across our facilities in Asia, we give our partners a unique offering.”